Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,658.00GBp
16 Aug 2019
Change (% chg)

12.40 (+0.75%)
Prev Close
1,645.60
Open
1,651.00
Day's High
1,662.00
Day's Low
1,642.00
Volume
4,838,752
Avg. Vol
6,932,268
52-wk High
1,749.40
52-wk Low
1,408.80

Select another date:

Wed, Aug 14 2019

Photo

AstraZeneca scores win in race to treat ovarian cancer

FRANKFURT AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

AstraZeneca scores win in race to treat ovarian cancer

FRANKFURT, Aug 14 AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK hands work on potential Ebola vaccines to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated. | Video

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated. | Video

WRAPUP 1-GSK raises 2019 earnings expectations after standout quarter for Shingrix

July 24 GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix

July 24 GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

Select another date: